Does TRICARE Cover Ozempic? Formulary Tier, Prior Authorization, and Appeal Steps

TRICARE Formulary Placement for Ozempic

Ozempic sits on the TRICARE Uniform Formulary as a non-preferred branded GLP-1 receptor agonist, which means it is available but carries both a prior authorization requirement and higher cost-sharing compared to preferred alternatives. The Department of Defense Pharmacy and Therapeutics Committee reviews formulary placement annually, and semaglutide's classification has remained stable since its inclusion.

For TRICARE Prime beneficiaries filling at a military treatment facility (MTF) pharmacy, copays can be $0 for formulary drugs dispensed on-site. At retail network pharmacies, expect a copay in the specialty tier range. TRICARE For Life beneficiaries (Medicare-eligible retirees) follow Medicare Part D formulary rules for retail fills, though MTF pharmacy access remains a zero-cost option when stock is available.

The distinction between preferred and non-preferred matters here. Preferred GLP-1 options on TRICARE, such as dulaglutide (Trulicity), may be available with lower cost-sharing and without prior authorization. The SUSTAIN-7 trial (N=1,201) demonstrated that semaglutide 0.5 mg and 1 mg produced greater A1C reduction (−1.5% and −1.8%) than dulaglutide 0.75 mg and 1.5 mg (−1.1% and −1.4%) at 40 weeks 1. That head-to-head superiority data becomes useful if your provider needs to justify why Ozempic, not dulaglutide, is medically necessary for your case.

The Ozempic prescribing information specifies its FDA approval for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise, and for reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease 2.

Prior Authorization Criteria for Ozempic on TRICARE

Getting Ozempic approved through TRICARE requires your prescriber to submit a prior authorization request to the regional managed-care support contractor (Humana Military for the East region, Health Net Federal Services for the West). The PA process is rated as moderate difficulty, not automatic but not as burdensome as some specialty medications.

Typical documentation requirements include a confirmed diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x), a recent A1C value (usually 7.0% or higher despite current therapy), evidence of trial and failure or intolerance of metformin for at least 90 days, and documentation showing inadequate control with at least one additional oral glucose-lowering agent such as a sulfonylurea or SGLT2 inhibitor. Some regional contractors also request documentation of BMI and cardiovascular risk factors, particularly if the provider is citing the cardiovascular indication.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as second-line agents after metformin for patients with established atherosclerotic cardiovascular disease, high cardiovascular risk, or when weight management is a treatment priority 3. Citing these guidelines in the PA request strengthens the clinical rationale. Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has noted: "GLP-1 receptor agonists have moved beyond glucose-lowering; the cardiovascular and renal benefits make them a foundational therapy for the right patient" 3.

PA approvals are typically granted for 12 months. Renewals require updated A1C values showing ongoing benefit.

Step Therapy Requirements Before Ozempic

TRICARE does require step therapy. This is standard across DoD formulary management for non-preferred agents.

The typical step-therapy sequence before Ozempic approval looks like this: first, a documented trial of metformin (minimum 90 days at maximally tolerated dose, often 1,500 to 2 to 000 mg daily). Second, trial of at least one additional oral agent, commonly a sulfonylurea (glipizide, glimepiride) or an SGLT2 inhibitor (empagliflozin, dapagliflozin). If glycemic targets remain unmet after these steps, the PA request for Ozempic becomes approvable.

Some beneficiaries can bypass step therapy. Documented metformin contraindications (eGFR <30 mL/min/1.73 m², history of lactic acidosis, severe gastrointestinal intolerance) allow your provider to request an exception. Similarly, patients with established atherosclerotic cardiovascular disease may qualify for earlier access to semaglutide based on the SELECT trial cardiovascular outcomes data, which showed a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg versus placebo over a median 39.8 months (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001) 4.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity supports the use of GLP-1 receptor agonists in patients with a BMI ≥30, or ≥27 with at least one weight-related comorbidity, though this applies to the obesity indication (Wegovy), not Ozempic's diabetes indication 5.

Does TRICARE Cover Ozempic for Weight Loss?

No. TRICARE does not cover Ozempic for weight loss. This is a critical distinction.

Ozempic is FDA-approved exclusively for type 2 diabetes. Prescribing it off-label for obesity is common in civilian practice, but TRICARE's formulary restricts coverage to FDA-approved indications. If a prescriber submits a PA for Ozempic listing an obesity diagnosis code (E66.x) rather than a diabetes code, the claim will be denied.

For military beneficiaries seeking GLP-1 therapy specifically for weight management, TRICARE does cover Wegovy (semaglutide 2.4 mg, the obesity-indicated formulation) and Zepbound (tirzepatide) with separate prior authorization. The PA criteria for these medications require documented obesity-medicine criteria: a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes), plus documentation of a structured lifestyle intervention.

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks compared with 2.4% in the placebo group 6. That data supports the Wegovy PA, not the Ozempic PA.

If you have both type 2 diabetes and obesity, the cleaner path is to have your provider prescribe Ozempic under the diabetes indication. The weight loss will still occur. The Endocrine Society recommends that when diabetes and obesity co-exist, selecting a glucose-lowering agent with weight-loss benefit is preferred over adding a separate anti-obesity medication 5.

How to Appeal a TRICARE Denial of Ozempic

Denials happen. The appeal process is straightforward if you follow the right steps.

When TRICARE denies a prior authorization for Ozempic, you receive a written explanation with the specific reason for denial. Common reasons include incomplete step-therapy documentation, missing A1C values, or a diagnosis code mismatch. Your first step is to review the denial letter for the exact deficiency cited. Many denials are resolved simply by resubmitting with the missing documentation attached.

For a formal appeal, submit a written request to your regional managed-care support contractor within 90 days of the denial notice. Include a letter of medical necessity from your prescriber explaining why Ozempic is specifically required (not just preferred) over formulary alternatives. Attach supporting clinical documentation: lab results, medication history with dates and doses of prior trials, any adverse reactions to alternative agents, and relevant guideline citations.

If the first-level appeal is denied, TRICARE offers a second-level review through an independent external reviewer. Beyond that, beneficiaries can escalate through the TRICARE ECHO (Extended Care Health Option) program for certain cases, or ultimately to the Defense Health Agency for a final determination.

Dr. Peter Lurie, former Associate Commissioner of the FDA, has stated: "Formulary restrictions serve a cost-management purpose, but clinical evidence should drive individual coverage decisions when a patient's prescriber documents medical necessity" 7.

Practical tip: keep a personal file with dates of every medication trial, the dose used, duration, reason for discontinuation, and any adverse effects. This documentation trail makes every future PA and appeal faster to assemble.

Out-of-Pocket Costs for Ozempic Under TRICARE

The manufacturer list price for Ozempic is approximately $998 per month for all dose strengths. What you actually pay depends on where you fill and which TRICARE plan you have.

At a military treatment facility pharmacy, TRICARE Prime beneficiaries pay $0 for formulary medications, including non-preferred drugs that have an approved PA. This is the most cost-effective option by a wide margin, though availability at MTF pharmacies can vary based on stock.

For TRICARE Prime at a retail network pharmacy, copays for non-preferred brand-name drugs are $77 for up to a 30-day supply (2026 rates). Through the TRICARE mail-order pharmacy (Express Scripts), the copay is $77 for a 90-day supply, making mail order roughly one-third the per-month cost of retail. TRICARE Select beneficiaries face higher cost-sharing: after meeting their annual deductible ($176 individual / $352 family for 2026), they pay 25% of the TRICARE-allowable charge for network pharmacy fills.

TRICARE For Life beneficiaries who are Medicare-eligible should note that if they fill at a retail pharmacy, Medicare Part D is the primary payer and TRICARE acts as secondary. In that scenario, the Part D formulary and cost-sharing structure applies. Filling at an MTF pharmacy bypasses Part D entirely.

One frequently asked question: can you use the Ozempic manufacturer savings card (Novo Nordisk's copay assistance program) with TRICARE? No. Federal law prohibits manufacturer copay cards from being applied to prescriptions covered by federal healthcare programs, including TRICARE, Medicare, Medicaid, and VA benefits 8. The savings card is available only to commercially insured or uninsured patients.

Switching from Ozempic to Alternatives on TRICARE

If the PA process proves too difficult or cost-sharing is a barrier, several alternatives sit in more favorable formulary positions on TRICARE.

Dulaglutide (Trulicity) is a preferred GLP-1 receptor agonist on the TRICARE formulary and often does not require prior authorization for the diabetes indication. It is dosed once weekly, like Ozempic, though SUSTAIN-7 data showed semaglutide produced greater A1C and weight reductions at comparable doses 1.

Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes. The SURPASS-2 trial (N=1,879) showed tirzepatide 15 mg reduced A1C by 2.30% versus semaglutide 1 mg's 1.86% reduction at 40 weeks 9. TRICARE formulary placement for tirzepatide varies by region and may also require PA. Check with your regional contractor for current status.

For beneficiaries already stable on Ozempic who face a formulary change or PA renewal difficulty, the American Diabetes Association recommends against switching glucose-lowering therapy purely for cost reasons if the current regimen is achieving glycemic targets and is well-tolerated 3. That guidance can be cited in a PA renewal or appeal.

Timeline and Practical Steps for Getting Ozempic Through TRICARE

The full process from first prescription to first injection typically takes 2 to 4 weeks when PA is required. Here is the practical sequence.

Your prescriber writes the Ozempic prescription and submits the PA request to the regional contractor (Humana Military East or Health Net Federal Services West). The contractor reviews the request, typically within 5 to 7 business days. If approved, the prescription can be filled. If denied, the denial letter arrives within 10 business days. A resubmission with additional documentation adds another 5 to 7 business days. A formal appeal adds 30 to 60 days.

To speed this up: have your prescriber's office include all step-therapy documentation, recent A1C, medication history, and a brief letter of medical necessity with the initial PA submission. Front-loading the paperwork avoids the most common reason for delay, which is the "request for additional information" cycle.

Active-duty service members have an additional pathway: their military treatment facility endocrinologist or primary care provider can sometimes prescribe and dispense Ozempic directly from MTF pharmacy stock without going through the civilian PA process, depending on the facility's formulary decisions and local stock availability. Check with your MTF pharmacy first.

The starting dose for Ozempic is 0.25 mg once weekly for 4 weeks, escalating to 0.5 mg, then optionally to 1 mg and 2 mg based on glycemic response and tolerability 2. PA approvals cover the full dose range, so you should not need a new PA when titrating up.